Ibrutinib, Single Agent BTK Inhibitor, for Treatment Naive (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: A Real-Life Experience from Rete Ematologica Pugliese (REP)

Conclusions: In our real life experience with data from REP, Ibrutinib single agent demonstred to be effective. In R/R patients, with a median time on study of 17 months, the estimated PFS at 30 m was 66.7%. The differences in PFS between patients with and without del17p was not statistically significant (p=0.543) but at 30 months the estimated PFS was lower in del17p pts than in no abnormality pts (65.1% vs 80.4%).The treatment was well tolerated with AEs of grade ≥3 in a low percentage (36%) that did not result in treatment interruptions in the most of cases. Clearly, these results will require longer follow up time to be further confirmed.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Scalzulli, P. R., Guarini, A., Loseto, G., Specchia, G., Giordano, A. M., Pastore, D., Quintana, G., Mazza, P., Maggi, A., Di Renzo, N., De Paolis, M. R., Tarantini, G., De Santis, G., Pavone, V., Greco, A., Valvano, M. R., Cascavilla, N. Tags: 642. CLL: Therapy, excluding Transplantation Source Type: research